221 related articles for article (PubMed ID: 6208100)
1. Characteristics of secondary acute nonlymphocytic leukemias. Cytological aspects (a review).
Raposa T; Várkonyi J; Gráf F
Folia Haematol Int Mag Klin Morphol Blutforsch; 1984; 111(2):180-5. PubMed ID: 6208100
[TBL] [Abstract][Full Text] [Related]
2. Acute leukemia after alkylating-agent therapy of ovarian cancer.
Reimer RR; Hoover R; Fraumeni JF; Young RC
N Engl J Med; 1977 Jul; 297(4):177-81. PubMed ID: 406560
[TBL] [Abstract][Full Text] [Related]
3. Acute nonlymphocytic leukemia after therapy with alkylating agents for ovarian cancer: a study of five randomized clinical trials.
Greene MH; Boice JD; Greer BE; Blessing JA; Dembo AJ
N Engl J Med; 1982 Dec; 307(23):1416-21. PubMed ID: 6752720
[TBL] [Abstract][Full Text] [Related]
4. [Leukemias induced by anticancer chemotherapies].
Harousseau JL
Bull Cancer; 1999 Nov; 86(11):929-38. PubMed ID: 10586109
[TBL] [Abstract][Full Text] [Related]
5. Risk of acute nonlymphocytic leukemia and preleukemia in patients treated with cyclophosphamide for non-Hodgkin's lymphomas. Comparison with results obtained in patients treated for Hodgkin's disease and ovarian carcinoma with other alkylating agents.
Pedersen-Bjergaard J; Ersbøll J; Sørensen HM; Keiding N; Larsen SO; Philip P; Larsen MS; Schultz H; Nissen NI
Ann Intern Med; 1985 Aug; 103(2):195-200. PubMed ID: 4014901
[TBL] [Abstract][Full Text] [Related]
6. Secondary myelodysplastic syndromes and leukemias.
Giles FJ; Koeffler HP
Curr Opin Hematol; 1994 Jul; 1(4):256-60. PubMed ID: 9371291
[TBL] [Abstract][Full Text] [Related]
7. Acute leukemia and immunosupressive drug use: a review of patients undergoing immunosuppressive therapy for non-neoplastic diseases.
Grünwald HW; Rosner F
Arch Intern Med; 1979 Apr; 139(4):461-6. PubMed ID: 373662
[TBL] [Abstract][Full Text] [Related]
8. Acute leukaemia after alkylating-agent therapy of ovarian cancer.
Bell DR; Woods RL; Levi JA
Med J Aust; 1982 Sep; 2(5):243-4. PubMed ID: 7132879
[No Abstract] [Full Text] [Related]
9. [Acute leukemia secondary to the treatment of multiple sclerosis with chlorambucil].
Aymard JP; Witz F; Conroy T; Lederlin P; Humbert JC; Barroche G; Streiff F
Rev Neurol (Paris); 1985; 141(2):152-4. PubMed ID: 3858929
[TBL] [Abstract][Full Text] [Related]
10. [Cytogenetic study of preleukemic phases and of acute leukemia secondary to chemo-and/or radiotherapy. Review of the literature (102 cases)].
Smadja N; Krulik M; Debray J
Pathol Biol (Paris); 1982 Nov; 30(9):775-83. PubMed ID: 6760082
[TBL] [Abstract][Full Text] [Related]
11. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
Nand S; Stock W; Godwin J; Fisher SG
Am J Hematol; 1996 May; 52(1):42-6. PubMed ID: 8638610
[TBL] [Abstract][Full Text] [Related]
12. Cytogenetic, clinical, and cytologic characteristics of radiotherapy-related leukemias.
Philip P; Pedersen-Bjergaard J
Cancer Genet Cytogenet; 1988 Apr; 31(2):227-36. PubMed ID: 3162396
[TBL] [Abstract][Full Text] [Related]
13. Development of acute nonlymphocytic leukaemia (ANLL) in myelomatosis.
Drivsholm A; Lisse I; Philip P
Scand J Haematol; 1985 Jul; 35(1):35-7. PubMed ID: 4048861
[TBL] [Abstract][Full Text] [Related]
14. [Induced leukemias. Cytogenetical and cytological aspects. Comparison with primitive leukemias (author's transl)].
Berger R; Bernheim A; Daniel MT; Valensi F; Flandrin G
Nouv Rev Fr Hematol (1978); 1981; 23(5):275-84. PubMed ID: 7329804
[TBL] [Abstract][Full Text] [Related]
15. Leukemia after treatment of ovarian cancer with alkylating agents.
Parker LM
N Engl J Med; 1983 Jun; 308(23):1422. PubMed ID: 6843637
[No Abstract] [Full Text] [Related]
16. Risk of leukemia associated with the first course of cancer treatment: an analysis of the Surveillance, Epidemiology, and End Results Program experience.
Curtis RE; Hankey BF; Myers MH; Young JL
J Natl Cancer Inst; 1984 Mar; 72(3):531-44. PubMed ID: 6583439
[TBL] [Abstract][Full Text] [Related]
17. Secondary acute leukemia following mitoxantrone-based high-dose chemotherapy for primary breast cancer patients.
Kröger N; Damon L; Zander AR; Wandt H; Derigs G; Ferrante P; Demirer T; Rosti G; ; ;
Bone Marrow Transplant; 2003 Dec; 32(12):1153-7. PubMed ID: 14647269
[TBL] [Abstract][Full Text] [Related]
18. Melphalan may be a more potent leukemogen than cyclophosphamide.
Greene MH; Harris EL; Gershenson DM; Malkasian GD; Melton LJ; Dembo AJ; Bennett JM; Moloney WC; Boice JD
Ann Intern Med; 1986 Sep; 105(3):360-7. PubMed ID: 3740675
[TBL] [Abstract][Full Text] [Related]
19. [Hodgkin's lymphoma and secondary leukemias].
Centurioni R; Brianzoni MF; Salvi A; Montillo M; Rupoli S; Olivieri A; Leoni P; Danieli G
Recenti Prog Med; 1993 May; 84(5):328-35. PubMed ID: 8511392
[TBL] [Abstract][Full Text] [Related]
20. Carcinogenic potency of alkylating agents in rodents and humans.
Dedrick RL; Morrison PF
Cancer Res; 1992 May; 52(9):2464-7. PubMed ID: 1568217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
